Tuesday, April 30, 2024
3:00 PM – 4:00 PM (EST)
No registration is required to participate - the Series is free and open to anyone. To participate, log in with your ASCO.org username and password. Create a new, free account or for assistance with your existing login.
Melissa Lynne Johnson, MD—Chair
Sarah Cannon Research Institute
Welcome and Introduction
Stephen V. Liu, MD
Georgetown University
Unmet Needs in Lung Cancer: KRAS as a Target (and Why It Has Been So Difficult)
Yuankai Shi, MD, PhD
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
ABSTRACT 468214: A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Julia K. Rotow, MD
Dana-Farber Cancer Institute
Discussion of Abstract 468214
Panel Question and Answer with Drs. Liu, Shi, and Rotow, Moderated by Dr. Johnson